产品描述: AZD3965是一种高效的,选择性的并且具有口服活性的monocarboxylate transporter 1 (MCT1)抑制剂,其结合亲和力为1.6 nM,比MCT2高6倍的选择性。Phase 1 |
靶点:
MCT1;Monocarboxylatetransporter |
体外研究:
在优先表达MCT1的淋巴瘤细胞系中,AZD3965有效的抑制了乳酸的转运以及细胞的生长。 AZD3965抑制了细胞中MCT1的活性,并在缺氧条件下展现出更高的敏感性。 在H526、HGC27和DMS114细胞中,AZD3965增加了细胞内的乳酸,并显著的减少了乳酸的摄入 |
体内研究:
在含有COR-L103肿瘤的非肥胖糖尿病scid-γ小鼠中,AZD3965 (100 mg/kg, p.o.)减少了肿瘤生长并增加了瘤内的乳酸。 在含有H526肿瘤的小鼠中,AZD3965 (100 mg/kg, p.o.) 增加了乳酸浓度,减少了肿瘤生长,增加了放射的敏感性 |
细胞实验:
Cell lines: DMS114, H526 and HGC27 cells Concentrations: 1.6 nM Incubation Time: 24 h Method: Cells were incubated in either normoxia, 1% oxygen (hypoxia) or anoxia in complete media supplemented with AZD3965 or DMSO vehicle for 24 hours. |
动物实验:
Animal Models: COR-L103肿瘤的非肥胖糖尿病scid-γ小鼠 Dosages: 100 mg/kg Administration: p.o. |
参考文献:
1. Critchlow SE, et al. Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1). 2012. AACR 103rd Annual Meeting. 2. Polański R, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014, 20(4), 926-937. 3. Bola BM, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014, 13(12), 2805-2816. |
溶解性:
Soluble in DMSO、Ethanol |
保存条件:
-20℃ |
配置溶液浓度参考:
|
1mg |
5mg |
10mg |
1 mM |
1.94 ml |
9.699 ml |
19.398 ml |
5 mM |
0.388 ml |
1.94 ml |
3.88 ml |
10 mM |
0.194 ml |
0.97 ml |
1.94 ml |
50 mM |
0.039 ml |
0.194 ml |
0.388 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |